Amsterdam-based Calypso Biotech to be Acquired by Swiss Medical company Novartis

Read also - UK-based Technology Company Travelport Secures $570m in New Equity Funding

Alain Vicari, Calypso’s Chief Executive Officer and co-founder, says, “We are excited about this transaction with Novartis, a company with a relentless commitment to developing innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively to address unmet medical needs in multiple indications promptly.”

Calypso is a Merck spin-out company that specialises in IL-15 biology and conducts research and development on monoclonal antibodies for a range of autoimmune diseases. In many chronic autoimmune disorders, IL-15 represents a broad, unexplored immunological axis that controls barrier function and downstream immune cascades.

Read also - Lyon-based ENYO Pharma Secures a €39 Million in Series C Round Funding

Bernard Coulie, Chairman of Calypso, says, “The transaction with Novartis constitutes the high point in the development path of CALY-002 for the team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody.”

Novartis is a firm that develops cutting-edge medications to enhance and prolong human life. According to Novartis, their medications are used by more than 250 million people globally and have a major influence on the healthcare sector.

Read also - Mental Health Startup Self Space Secures €2.6 million Seed Funding

Richard Siegel, Head of Immunology Research at Novartis, comments, “Novartis is committed to bringing innovative treatment options forward for patients with immunological diseases. We’re thrilled to add Calypso’s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.”

About Novartis

Novartis is a cutting-edge pharmaceutical firm. reimagining medicine every day to prolong and improve people's lives, empowering patients, healthcare providers, and society at large in the face of serious illness. Over 250 million people globally are able to access our medications.

Read also -  Manchester-based Holiferm Raises €21.4M in Series B Round Funding

About Calypso Biotech BV

With a specialisation in IL-15 biology, Calypso Biotech BV is a private biotechnology firm dedicated to the investigation and creation of innovative biologics to meet unmet medical needs in autoimmune and inflammatory illnesses. Together with its widespread impact on inflammation, IL-15 regulates immunological pathways that are vital to the development and maintenance of disease (known as "disease memory"), as well as tissue damage.

Read also - London-based Vortexa Secures $34M in Series C Round Funding